CatalystCorporate
AMYLYX STOCK SOARS AFTER ITS GLP-1 BLOCKER CUT DANGEROUS LOW-BLOOD-SUGAR EVENTS IN TRIAL - QZ
GLP-1 trial data cut hypoglycemia events, driving Amylyx stock surge.
What changed
GLP-1 trial data cut hypoglycemia events, driving Amylyx stock surge.
Why it matters
GLP-1 trial data cut hypoglycemia events, driving Amylyx stock surge. — impact context not separately stored; see What changed.
← Dashboard
Aug 18, 2026 07:45 PM ET